Vaxxinity, Inc. financial data

Symbol
VAXX on OTC
Industry
Pharmaceutical Preparations
Location
505 Odyssey Way, Exploration Park, FL
State of incorporation
FL
Fiscal year end
December 31
Latest financial report
10-K - Q4 2023 - Mar 27, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 238 % -39.1%
Debt-to-equity 119 % +159%
Return On Equity -193 % -126%
Return On Assets -88 % -50.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 127M shares
Entity Public Float 156M USD +64.7%
Weighted Average Number of Shares Outstanding, Basic 127M shares +0.45%
Weighted Average Number of Shares Outstanding, Diluted 127M shares +0.45%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 50K USD
Research and Development Expense 35.9M USD -24.6%
General and Administrative Expense 22.4M USD -21%
Operating Income (Loss) -58.3M USD +23.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -18.3M USD +43%
Net Income (Loss) Attributable to Parent -56.9M USD +24.3%
Earnings Per Share, Basic -0.45 USD/shares +25%
Earnings Per Share, Diluted -0.45 USD/shares +25%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.93M USD -85.3%
Cash, Cash Equivalents, and Short-term Investments 56.1M USD
Assets, Current 33.2M USD -64.6%
Property, Plant and Equipment, Net 11.1M USD -11.4%
Assets 44.3M USD -58.4%
Accounts Payable, Current 2.97M USD -10.4%
Employee-related Liabilities, Current 1.56M USD -39.3%
Accrued Liabilities, Current 4.74M USD
Liabilities, Current 17.6M USD -43.1%
Other Liabilities, Noncurrent 35K USD -85.2%
Liabilities 30.9M USD -30.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 8K USD
Retained Earnings (Accumulated Deficit) -362M USD -18.7%
Stockholders' Equity Attributable to Parent 13.4M USD -78.4%
Liabilities and Equity 44.3M USD -58.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -20.1M USD -2.75%
Net Cash Provided by (Used in) Financing Activities -574K USD -4200%
Net Cash Provided by (Used in) Investing Activities 8.74M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -11.9M USD +41.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.04M USD -85.4%
Interest Paid, Excluding Capitalized Interest, Operating Activities 192K USD +109%
Deferred Tax Assets, Valuation Allowance 61.4M USD +24.8%
Deferred Tax Assets, Gross 61.4M USD +24.7%
Operating Lease, Liability 500K USD +150%
Depreciation 586K USD +76%
Payments to Acquire Property, Plant, and Equipment 172K USD -75.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -13.1M USD +32.5%
Property, Plant and Equipment, Gross 16.9M USD +5.03%
Deferred Tax Assets, Operating Loss Carryforwards 42.2M USD +7.62%
Preferred Stock, Shares Authorized 50M shares 0%
Unrecognized Tax Benefits 35K USD -94.6%
Additional Paid in Capital 375M USD +2.17%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 42K USD -50%
Share-based Payment Arrangement, Expense 7.51M USD -13.8%
Interest Expense 696K USD +35.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%